Posts by Mourabit Halima

Breast cancer remains a leading malignancy threatening women’s health, and optimizing treatment strategies continues to be a major focus of research. Neoadjuvant therapy, especially for HER2-positive breast cancer, plays a key role in improving survival outcomes and quality of life. The 47th San Antonio Breast Cancer Symposium (SABCS) will take place from December 10 to 13, 2024, in San Antonio, Texas. Professor Wenbin Zhou and his team from Jiangsu Province Hospital will present a study (Poster Abstract No: P3-11-24) evaluating the efficacy of pyrotinib combined with trastuzumab and nab-paclitaxel in HER2-positive breast cancer. The results demonstrate an impressive pathological complete response (tpCR) rate in HER2-enriched patients, with good tolerability and controllable safety. This innovative therapy offers new hope for HER2-positive breast cancer patients and supports precision treatment strategies.

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, Texas, USA. As the largest and most influential breast cancer-focused academic meeting globally, the conference will unveil a series of groundbreaking research findings. A study conducted by Dr. Hui Xie and her team from The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)was selected for poster presentation (Abstract No: P3-01-19). The research employs proteomics to explore the degradomic characteristics of mammary tumor-adjacent adipocytes, revealing that the peptide MASP6 promotes breast cancer invasion and metastasis and may serve as a personalized biomarker and therapeutic target. This article provides an overview of the study.

Previous studies have demonstrated that short-term efficacy metrics, such as objective response rate (ORR), are associated with long-term survival outcomes, such as overall survival (OS), in targeted therapy for advanced hepatocellular carcinoma (HCC). At the 2024 International Liver Cancer Association (ILCA) Conference, Professor Masatoshi Kudo from Kinki University Faculty of Medicine in Japan presented exploratory analyses on the correlation between efficacy metrics like depth of response (DpR) and duration of response (DoR) with OS benefits. He also discussed their value in guiding systemic drug therapy combined with local treatments. We interviewed Professor Kudo to share his key findings.

The European Society for Medical Oncology Asia (ESMO Asia) Congress was held in Singapore，from 6 to 8 December 2024. ESMO Asia is an annual congress specifically focused on multidisciplinary oncology in the Asian region, providing a remarkable platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field. During the three-day event, Qilu Pharmaceutical unveiled the latest findings from three key studies on iparomlimab and tuvonralimab (QL1706), a bifunctional MabPair® product of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.

Muscle-invasive bladder cancer (MIBC) presents unique challenges due to its aggressive nature and the complexity of its treatment. At ESMO Asia 2024, Dr. Brigida Maiorano shared valuable insights into evolving strategies, including bladder-preserving approaches, novel clinical trial designs, and the latest advances in targeted therapies. In this exclusive interview with Oncology Frontier, Dr. Maiorano discusses current standards, promising clinical results, and her vision for improving outcomes in MIBC.